Fig. 1 · Structure

Documents & Downloads

Isoacteoside

Cat. No. A12071 CAS 61303-13-7
Isoacteoside is a natural compound which exhibit significant inhibition of advanced glycation end product formation with IC50 values of 4.6-25.7 μM, compared with those of aminoguanidine (IC50=1,056 μM) and quercetin (IC50=28.4 μM) as positive controls.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
HEp-2 EC50 0.62 μg/mL Antiviral activity against RSV long infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days [PMID: 9599250]
HEp-2 EC50 1.1 μg/mL Antiviral activity against RSV A-2 infected in human Hep2 cells after 3 days by plaque neutralization assay [PMID: 9599250]
HEp-2 IC50 27 μg/mL Cytotoxicity against HSV2 infected human Hep2 cells after 3 days [PMID: 9599250]
HEp-2 IC50 30 μg/mL Cytotoxicity against HSV1 infected human Hep2 cells after 3 days [PMID: 9599250]
HEp-2 IC50 51.4 μg/mL Cytotoxicity against RSV long infected human Hep2 cells after 3 days [PMID: 9599250]
HEp-2 IC50 75 μg/mL Cytotoxicity against VZV 3CV-1 infected human Hep2 cells after 3 days [PMID: 9599250]
HEp-2 IC50 89 μg/mL Cytotoxicity against mCMV RM-461 infected human Hep2 cells after 3 days [PMID: 9599250]
Hepatocyte IC50 5.3 μM Hepatoprotective activity in ddY mouse primary cultured hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity after 44 hrs by MTT assay [PMID: 20159656]
L929 IC50 22.7 μg/mL Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity after 44 hrs by MTT assay [PMID: 20159656]

9 records · Scroll to view more

Isoacteoside Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Isoacteoside from 3 published references. In vitro models include A549 lung cancer cell line; mouse macrophage RAW 264.7 cells.

Isoacteoside In Vitro Studies

Isoacteoside exposure decreased A549 lung cancer cell viability dose-dependently after 24 h, with an IC50 of 393.10 ± 15.27 µg/mL. In mouse macrophage RAW 264.7 cells evaluated with Isoacteoside, the reported comparison involving different target compounds of O. vulgaris found no significant proliferation difference versus control at 6.25 μM, 12.5 μM, 25 μM, 50 μM, and 100 μM. Isoacteoside also induced tumor cell apoptosis in HCC cells assessed by flow cytometry. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cell Viability in Lung Cancer Cells

Cell-based study · A549 lung cancer cell line [1]

A549 lung cancer cells were exposed to Isoacteoside for 24 h, with untreated cells as control. Cell viability decreased dose-dependently, with an IC50 of 393.10 ± 15.27 µg/mL.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell viabilityIC50 24 h: IC50 393.10 ± 15.27 µg/mL[1]

Literature-Reported Treatment Conditions

Treatment concentration
12.5, 25, 50, 100, 200, 400, 600, 800, and 1000 µg/mL
Exposure duration
24 h
Method
exposure
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Isoacteoside; Compound label in the paper: isoverbascoside

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Method > 2.9. Determination of Cytotoxicity of C. chinense Leaf Extract and Bioactive Compounds Using Sulforhodamine B (SRB) Assay (S72, S74); 3. Results > 3.8. Determination of Cytotoxicity of C. chinense Leaf Extract and Bioactive Compounds Using Sulforhodamine B (SRB) Assay (S157, S164, S165, S166); Figure 3 legend (S205)

cell viability: cell viability; comparator: untreated cells — 2. Materials and Method > 2.9. Determination of Cytotoxicity of C. chinense Leaf Extract and Bioactive Compounds Using Sulforhodamine B (SRB) Assay (S74); 3. Results > 3.8. Determination of Cytotoxicity of C. chinense Leaf Extract and Bioactive Compounds Using Sulforhodamine B (SRB) Assay (S165, S166); Figure 3 legend (S205)

Macrophage proliferation in an Isoacteoside evaluation

Cell-based study · mouse macrophage RAW 264.7 cells [2]

Isoacteoside was evaluated in mouse macrophage RAW 264.7 cells during 48 h of culture. The reported comparison found no significant difference in proliferation between control cells and cells treated with different target compounds of O. vulgaris at 6.25 μM, 12.5 μM, 25 μM, 50 μM, and 100 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
proliferation activityReported result there was no significant difference between the proliferation of control cells and that of RAW 264.7 cells upon treatment with different target compounds of O. vulgaris at 6.25 μM, 12.5 μM, 25 μM, 50 μM, and 100 μM (p > 0.05)[2]

Literature-Reported Treatment Conditions

Treatment concentration
6.25, 12.5, 25, 50, 100, and 200 μM
Exposure duration
48 h of culture
Method
added to the culture
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Isoacteoside

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Anti-Inflammatory Assay > Effects of the Target Compounds of O. vulgaris on Cell Viability (S96, S97, S99); Results > Anti-Inflammatory Assay > Protective Effects of Target Compounds on LPS-Treated RAW 264.7 Cells (S185, S186)

proliferation activity: proliferation activity; comparator: normal control group (without the extract) — Results > Anti-Inflammatory Assay > Protective Effects of Target Compounds on LPS-Treated RAW 264.7 Cells (S185, S186)

Isoacteoside and tumor cell apoptosis

Cell-based study · HCC cells [3]

HCC cells were treated with Isoacteoside, with a negative control for comparison. Flow cytometry showed induced tumor cell apoptosis.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Flow cytometryReported result induced tumor cell apoptosis[3]

Literature-Reported Treatment Conditions

Vehicle
dimethylsulfoxide (DMSO, #D8371, Solarbio)
Reported limits
Not stated in the sentences used: dose, route, schedule.
Methods and source locations

Compound reported in the paper: Isoacteoside

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > The combination of isoacteoside and sorafenib significantly increased the therapeutic efficacy of HCC (S119, S120, S127); Methods > Drug, cytotoxicity, and sorafenib resistance testing (S199); Methods > Apoptosis analysis (S209)

Flow cytometry: Flow cytometry; comparator: negative control — Results > The combination of isoacteoside and sorafenib significantly increased the therapeutic efficacy of HCC (S120, S127)

Isoacteoside In Vivo Studies

C57BL/6 mice received Isoacteoside at 30 mg/kg by intraperitoneal injection, with saline solution as control. No significant effect on body weight changes was reported. [3]

Body Weight Assessment in Mice

Animal study · C57BL/6 mice were divided into 2 groups (n = 4) [3]

C57BL/6 mice received Isoacteoside at 30 mg/kg by intraperitoneal injection, with saline solution as control. No significant effect on body weight changes was reported.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Body weight was recorded every two daysReported result HY-N0022 at a dose of 30 mg/kg via intraperitoneal injection for two weeks, with the initial dose being doubled: HY-N0022 had no significant effect on body weight changes in mice at the recommended dosage.[3]

Conditions shared by the study groups

Route
intraperitoneal injection
Treatment course
for two weeks, with the initial dose being doubled
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Isoacteoside 30 mg/kgsaline solutionHY-N0022 at a dose of 30 mg/kg via intraperitoneal injection for two weeks, with the initial dose being doubled: HY-N0022 had no significant effect on body weight changes in mice at the recommended dosage.[3]
Isoacteoside 30 mg/kg
Model: C57BL/6 mice were divided into 2 groups (n = 4)
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Isoacteoside

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > The combination of isoacteoside and sorafenib significantly increased the therapeutic efficacy of HCC (S131); Methods > Animal experiments (S221, S222, S223)

Body weight was recorded every two days: Body weight was recorded every two days; comparator: saline solution — Results > The combination of isoacteoside and sorafenib significantly increased the therapeutic efficacy of HCC (S131); Methods > Animal experiments (S222, S223)

Isoacteoside 30 mg/kg · Results > The combination of isoacteoside and sorafenib significantly increased the therapeutic efficacy of HCC (S131); Methods > Animal experiments (S222)

Specifications

Manufacturer Adooq Bioscience
CAS Number 61303-13-7
Formula C29H36O15
Molecular Weight 624.59
Synonyms Acteoside isomer
SMILES
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2[C@@H]([C@H](O[C@H]([C@@H]2O)OCCC3=CC(=C(C=C3)O)O)COC(=O)/C=C/C4=CC(=C(C=C4)O)O)O)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 88 mg/mL (140.89 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Isoacteoside Research References

  1. [1] Chittasupho C, Athikomkulchai S, Samee W, et al. Phenylethanoid Glycoside-Enriched Extract Prepared from Clerodendrum chinense Leaf Inhibits A549 Lung Cancer Cell Migration and Apoptosis Induction through Enhancing ROS Production. Antioxidants (Basel) (2023). PMID: 36830019 DOI: 10.3390/antiox12020461 Source material
  2. [2] Ji M, Wang C, Yang T, et al. Integrated Phytochemical Analysis Based on UPLC-MS/MS and Network Pharmacology Approaches to Explore the Effect of Odontites vulgaris Moench on Rheumatoid Arthritis. Front Pharmacol (2021). PMID: 34526896 DOI: 10.3389/fphar.2021.707687 Source material
  3. [3] Zhao L, Qi H, Liu W, et al. Isoacteoside alleviates hepatocellular carcinoma progression by inhibiting PDHB-mediated reprogramming of glucose metabolism. Commun Biol (2025). PMID: 39922943 DOI: 10.1038/s42003-025-07622-x Source material

Added to your cart

View Cart Checkout
Loading...